Get To Know Us

Veronica L. Hall, Ph.D.

Veronica L. Hall, Ph.D.

Chief Development Officer, Head of R&D

Veronica Hall, PhD, has a multidisciplinary background with more than 20 years of experience in life science research, including conception, design, and delivery of technical and commercialization solutions for vaccines, therapeutics, and drug/device combinations. Over the course of her career, Dr. Hall has successfully led R&D and partnership efforts, leading teams large and small for a range of small to mid-size biotech firms. She served as Senior Director at Emergent BioSolutions Inc. leading the strategic R&D pipeline growth. Dr. Hall received a Bachelor of Science in Biochemistry and Molecular Biology from University of California, Santa Cruz, and a Ph.D. in Biochemistry and Cellular Biology from Rice University. She completed her postdoctoral fellowship at the National Cancer Institute.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.